Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Humberto Aguilar et al.|The Lancet|2019Cited by 1.2k
Current epidemiology of chronic liver diseaseRichie Manikat, Donghee Kim, Aijaz Ahmed|Gastroenterology report|2023Cited by 56
The prevalence and predictors of metabolic dysfunction‐associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adultsBrandon J. Perumpail, Donghee Kim, Richie Manikat et al.|Journal of Pediatric Gastroenterology and Nutrition|2024Cited by 25
Up-to-date global epidemiology of nonalcoholic fatty liver diseaseRichie Manikat, Donghee Kim, Aijaz Ahmed|HepatoBiliary Surgery and Nutrition|2023Cited by 24
Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023Donghee Kim, Aijaz Ahmed, Richie Manikat et al.|Clinical and Molecular Hepatology|2024Cited by 22